Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.67 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621565 | 1.00 | ESR2 (0.67) | ESR2NR1H2ABHD6GPR119CA1 | |
| SCHEMBL19682381 | 0.95 | NR1H2 (0.66) | ESR2NR1H2ABHD6GPR119CA1 | |
| SCHEMBL14157494 | 0.90 | ESR2 (0.52) | ESR2NR1H2GPR119STSMAPK1 | |
| SCHEMBL4789776 | 0.89 | ESR2 (0.69) | ESR2NR1H2GPR119 | |
| SCHEMBL31020127 | 0.89 | ESR2 (0.69) | ESR2NR1H2GPR119 | |
| SCHEMBL31621666 | 0.88 | ESR2 (0.67) | ESR2NR1H2ABHD6GPR119CA1 | |
| SCHEMBL30643119 | 0.82 | ESR2 (0.70) | ESR2NR1H2ABHD6ESR1MAPK1 | |
| SCHEMBL2568732 | 0.82 | ESR2 (0.70) | ESR2NR1H2ABHD6ESR1MAPK1 | |
| SCHEMBL19684692 | 0.82 | ESR2 (0.78) | ESR2NR1H2ABHD6STSESR1 | |
| SCHEMBL31621670 | 0.82 | ESR2 (0.78) | ESR2NR1H2ABHD6STSESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703776-B | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024165050-A1 | PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD | AUBRAK THERAPEUTICS (CN) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | ESR2 1259/4885NR1H2 930/4885ABHD6 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.